Introduction
Histone post-translational modifications represent a fundamental mechanism for regulating DNA accessibility in various DNA-templated processes such as gene transcription 1 .
Dysregulationofchromatin modifying mechanismsis one of the central oncogenic pathways in human cancer [1] [2] [3] , including B-cell malignancies [4] [5] [6] .
Among various chromatin-modifying factors, polycomb group (PcG) proteins are critical for controlling gene expression, maintaining the repressive chromatin states, and defining cellular identities during development 7, 8 .PcG proteins act in multimeric complexes known as PolycombRepressive Complexes (PRC); two major PcG complexes exist in mammalian cells-PRC1 and PRC2. Biochemically, PRC1 employs an E3 ligase, RING1A or RING1B, to induce mono-ubiquitination of histone H2A, lysine 119 (H2AK119ub1) (Figure 1 ), a reaction that requires essential cofactors such as BMI1 8 . PRC2 utilizes an enzymatic subunit, Enhancer of zeste homologue 2 (EZH2) or related EZH1, to methylate histone H3, lysine 27 (H3K27, Figure 1 other PRC2 subunits (EED, SUZ12) and accessory cofactors such as JARID2 and polycomb-like (PCL) harbor either DNA-or histone-binding activities to modulate PRC2 activity and mediate its targeting or spreading on chromatin [7] [8] [9] . H2AK119ub1 and H3K27 tri-methylation (H3K27me3) are prominent histone marks associated with gene silencing, indicating a causal role of PcGmediated enzymatic activity in transcriptional regulation 7, 8 .H3K27me3 also coexists with thegene activation-associated H3K4me3 at "bivalent domain genes" to maintain genes in a repressed but poised conformation, which can be subsequently activated or stably repressed according to lineage-specific differentiation programs 1 
.
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In a simplistic hierarchical model, PRC2 acts upstream of PRC1 as H3K27me3 serves as a 'docking' site for CBX, a chromodomain-containing protein ( Figure 1A ), which then recruits PRC1 to induce H2AK119ub1 7, 8 ( Figure 1B ). However, more recently, data has demonstrated that PRC1recruitment is both PRC2-dependent and PRC2-independent 10, 11 .Furthermore, recent studies show that PRC1 can act upstream of PRC2. In this case, a PRC1 variant utilizes KDM2B, a CxxC-domain protein, to bind to the non-methylated CpG sequence where PRC1-induced H2AK119ub1 recruits PRC2 via an unknown mechanism [12] [13] [14] ( Figure 1C ). EED, a PRC2subunit, also physically interacts with PRC1 thus linking PRC2 to PRC1 15 . Overall, PRC2 and PRC1
cooperate and enforce gene silencing via positive feedback loops.
Increasing evidence has revealed crucial roles of PcG proteins in myriad biological processes, including self-renewal, differentiation, cell cycle control, senescence, and gene expression and imprinting 7, 8, 16, 17 , all of which have been linked to oncogenesis when deregulated.Notably, PcG genes were found mutated in B-cell malignancies. B lymphoma Mo-MLV insertion region 1 homolog (BMI1) was originally isolated as a gene up-regulated in murine B-cell lymphomas 18 ; recurrent gain-of-function mutations of EZH2 were identified in germinal center (GC) B-cell lymphomas 4, 19, 20 . Here, we focus on deregulations of PcG and cofactors during the initiation and development of B-cell malignancies. We also discuss the interplays between PcG and other epigenetic regulators such as miRNAs, histone deacetylases (HDACs) and DNA methytransferases (DNMTs). Finally, we summarize recentprogress in development of PcGspecific inhibitors as novel therapies of B-cell malignancies.
Biological function of PcG proteins in B-cell development and lymphomagenesis
The development and differentiation of B-cell lineages initially occurs with progenitor B-cell expansion and V(D)J gene rearrangement, a DNA recombination process that produces clonally unique, immunoglobulin variable regions for antigen recognition 21 . Upon antigen stimulation, Bcells undergo activation through proliferation, somatic hyper-mutation, and antibody class switching, which occur in the GCs of secondary lymphoid tissues. A proliferative feature of GC B lymphocytes, with concomitant attenuation of their DNA damage repair function and ongoing somatic hyper-mutation, increases the likelihood of oncogenic mutation, genomic instability, and subsequent lymphomas. B-cell development is tightly controlled by genetic and epigenetic mechanisms, including DNA methylation, histone modification, chromatin remodeling 22 , and noncoding RNAs 23 . During normal B lymphocyte differentiation, expression of PRC1 and PRC2 genes shows a restricted, stage-specific pattern. BMI1 and its PRC1 partners are primarily detected among resting B-cells in the GC mantle zone and in non-dividing centrocytes of the GC follicles; these PRC1 genes are silenced in proliferating follicular centroblasts, which then express the PRC2 genes instead [24] [25] [26] . In contrast, lymphomas generally lose such a mutually exclusive expression pattern, and altered expression of PRC1 and PRC2 genes are a general theme in lymphomas, including diffuse large B-cell lymphomas (DLBCL) 27 , follicular lymphomas (FL), and mantle cell lymphomas (MCL) 28 . These findings suggest essential regulatory roles of PRC1 and PRC2 in both normal B lymphocyte development and lymphoma pathogenesis.
PRC1 in B-cell development and lymphomagenesis
BMI1.Bmi1 was initially discovered from a locus activated by viral integration in murine lymphomas 18 . BMI1 controls a range of B-cell developmental genes including lineage master regulators Ebf1 and Pax5
29
. Bmi1 deficiency causes conversion of the "bivalent domain" 29 . BMI1 alsodirectly represses expression of the tumor suppressors p16Ink4a/p19Arf and p15Ink4b, therefore BMI1 over-expression prevents c-MYC-mediated apoptosis and was sufficient to induce lymphoma, a process accelerated by c-MYC 18, 30 .Furthermore, BMI1 represses the pro-apoptotic genes Noxa and Bim, supporting its prosurvival role in B-cell development and lymphomas 31, 32 .In human B-cell lymphomas, BMI1 overexpression is common in almost all subtypes 33 . Expression of BMI1 alone or in combination with EZH2 characterizes aggressive B-cell lymphomas with unfavorable prognosis 27, 33, 34 .
Recently, a novel t(10;14)(p12;q32) translocation was identified in chronic lymphocytic leukemia and MCLs leading to IgH-BMI1 rearrangement and BMI1 overexpression 35 ; IgH-BMI1 rearrangement was acquired during tumor high-grade transformation and correlated with chemoresistance 35 . Transcriptome analyses of multiple cancers found that BMI1-driven gene signatures define a phenotype of cancer stem cells 36 , suggesting that BMI1 confers malignant cells with features of cancer stem cells, the rare cancerous subpopulations that confer drug resistance and regeneration abilities 16, 37 . Indeed, BMI1-mediated repression of p16Ink4a/p19Arf was shown to be essential for self-renewal of hematopoietic stem cells 38 . Overall, these studies support critical roles of BMI1 in promoting lymphoma progression and conferring therapy resistance. harbors both oncogenic and tumor suppressive roles in different contexts, which is reminiscent ofPRC2's dual functions described among different hematopoietic malignancies [43] [44] [45] _ENREF_57.
PRC2 in B-cell development and lymphomagenesis
EZH2 is highly expressed in lymphoid progenitors and required for efficient V(D)J recombination in pro-B cells 46 . EZH2 is silenced in resting GC B-cells but massively up-regulated when GC Bcells get activated and undergo rapid proliferation and immunoglobulin affinity maturation 26, 47 ; EZH2 blocks the DNA damage response pathways, allowing cells to survive the somatic hypermutation during antibody maturation 26 .Expression of EZH2strongly associates with B-cell malignancies, with its high levels correlated with the Ki67 labeling index, lymphoma aggressiveness, and unfavorable prognosis 33, 34 . . These EZH2 mutations are likely to be early lesions during lymphomagenesis 6, 49 .Biochemically, EZH2
Y641
mutations alter substrate specificity of EZH2 19, 20, 50 .Being a catalytic subunit of PRC2, EZH2 induces sequential mono-, di, and trimethylation of H3K27, with the highest methylation status most strongly associated with gene silencing 51 . Wild-type EZH2 has a greater catalytic efficiency for conducting mono-methylation of H3K27 (H3K27me1) and a diminished efficiency for subsequent reactions (mono-to-di, and di-totri methylations) 19, 20, 50 .In contrast, lymphoma-associated EZH2
Y641X mutations (X meansAsn/Phe/Ser/His/Cys) show the exactly opposite substrate specificity, displaying limited ability to induce H3K27 mono-methylation,yet extremely high efficiencyforcatalyzing the H3K27di-to-trimethylation reaction 19, 20, 50 . In contrast with the oncogenic role of EZH2 in B-cell lineages, the tumor suppressive roles of PRC2 in T-cell acute lymphoblastic leukemia 44, 45 and myeloid malignancies 43 were identified due to a range of missense, nonsense, and frame-shift mutations in EZH2, SUZ12,or EED( Figure 1 ). .These studies emphasize the complicated, context-dependent role of PRC2 in oncogenesis, which might be due to a tightly controlled expression pattern of EZH2 throughout B-cell lineage differentiation. As a result,PRC2
activityatvarious developmental stages may eithersuppress or facilitate lymphomagenesis.
Indeed, EZH2 expression is high in pro-B cells, decreased in pre-B cells, and becomes nearly undetectable in immature naïve cells 46, 57 ; EZH2 is then up-regulated again during affinity maturation in GC B-cells 26, 47 . Therefore, it could be the case that, while PRC2 restricts the proliferative and self-renewal potential of immature B-lymphoid progenitors, its gain-of-function mutations stimulate proliferation specifically in maturing GC B-cells.Further work with mouse models engineered to overexpress or delete EZH2 at each specific stage of B-cell differentiation shall provide insight into the role of PRC2 invarious B-cell malignancies.
Interplay of PcG with other epigenetic enzymes
In addition to intrinsic enzymatic functions, PcG complexes also recruit other chromatin-modifying . Loss-offunction mutations of TrxG and gain-of-function mutations of PcGgenes may perturb a fine equilibrium of histone methylation dynamics during B-cell lymphomagenesis.
Interplay of PcG with miRNAs
MicroRNAs (miRNAs) are 22-nucleotide, non-coding single-stranded RNAs that can repress gene expression at a post-transcriptional level. miRNAs are increasingly recognized as one of the major players in numerous biological processes, and their down-deregulation is often seen in tumors, suggesting their tumor suppressive roles. It can be anticipated that miRNAderegulation can contribute to PcG deregulation. Indeed, EZH2 was the first PcG gene shown to be regulated by miRNA 67, 68 . By targeting the 3′-untranslated region of EZH2 mRNA, miR-101 and miR-26 repress cellular EZH2 levels 83, 84 . miRNAs that repress PRC1 genes were also identified [69] [70] [71] . Down-regulation and deletion of these miRNAs are frequent in various tumors including prostate cancer and lymphomas 67, 68 . Conversely, PcG proteins also contribute to miRNA expression and deregulation during malignant development, given their frequent alterations found in tumors.
Indeed, many miRNA genes are repressed by PRC2 and demarcated with H3K27me3 ; miR-15a/16-1 targets BCL2 and acts as tumor suppressor in chronic lymphocytic leukemia 81 . Interestingly, severalof these c-MYC-repressed miRNAs including miR-26a, miR-101, and let-7 actually repress EZH2directly 67, 75, 78 ( Figure 3B) ; miR-29, a family of miRNAsknown to beinvolved in B-cell lymphomagenesis 75, 82 , was shown to downregulate DNMT3A, a PRC2-interacting factor,in chronic lymphocytic leukemia 83 ( Figure 3B ).
Thus, via recruitment of PRC2 and HDACs, c-MYC, a prominent lymphoma-promoting factor, repressesmiRNAs that negatively regulate EZH2 and its cofactors, establishing a positive
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From feedback loop for enforcing polycomb expression and functionality in B-cell lymphomas. As knocking down EZH2 and HDACs led to re-expression of the MYC-repressed miRNAs 75, 78, 84, 85 , the existing pharmacological agents for inhibition of these c-MYC-associated co-repressors shall represent a promising way to disrupt such a vicious amplification loop associated with lymphomagenesis.
Epigenetic therapy and perspective
Epigenetic deregulation of chromatin structure and function leads to aberrant gene expression and oncogenesis. Consequently, epigenetic therapies aim to restore normal chromatin modification patterns through inhibition of the deregulated epigenetic machinery. HDAC and DNMT inhibitors are among the first promising agents for epigenetic therapies 2 . This study implicates that BMI1 has the potential to be developed as a drug target for treating B-cell lymphomas with BMI1 overexpression.
Targeting PRC2Several highly selective small-molecule inhibitors of PRC2 (with K i values within the low nanomolar range) have recently been discovered [87] [88] [89] [90] [91] [92] [93] , many of which possess a common pyridone-containing motif that confers EZH2 or EZH1 inhibition ( Figure 4A ). Among them, EPZ005687_ENREF_112 and GSK126 87 show high selectivity for EZH2 versus other
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From methyltransferases, with >50-150-fold selectivity for EZH2 over EZH1 ( Figure 4A ). Early success was seen in treating B-cell lymphomas bearing EZH2 gain-of-function mutation with these inhibitorsin DLBCL xenografts in mice 56, [87] [88] [89] [90] [91] [92] [93] . GSK126 87 , EPZ005687 and EPZ-6438 88, 94 ( Figure   4A -B)show their particular effectiveness in suppressing growth of the EZH2-mutant lymphomas versus those with wild-type EZH2. At the transcriptome level, andin contrast to minimal transcriptional responses in EZH2-wildtype drug-insensitive lines, re-activation of the formerly H3K27me3-demarcated genes was generally seen in drug-sensitive GCB-DLBCL lines 87, 93 .However, only a limited number of up-regulated genes were found common across , providing rational for a personalized medicine for lymphoma therapy. Furthermore, the efficacy of EZH2 inhibitorshas beenestablishedin various B-cell lymphomas with wild-type EZH2
including MCLs and Burkitt's lymphoma 75, 93 . Therefore, other molecular determinants for EZH2 inhibitor sensitivityremain to be defined for B-cell lymphomasin order to improve the personalized therapy. Such genetic determinants were defined in other cancers including SNF inactivation in malignant rhabdoidtumors 91 , MMSET/NSD2 translocation in multiple myeloma 99 , and MLL rearrangementin acute leukemia 95, 100 , and all of these affected pathways have been connectedto PRC2 genetically.Thus, it is likely that lymphoma carrying TrxG gene mutations 5, 6, 66 such as MLL2 mutations may render sensitivity to PRC2 inhibition.
Furthermore, it remains to be examined if EZH1, a less-studied EZH2-related enzyme,is overexpressed in B-cell malignancies and if EZH1 inhibition improves the therapeutic potential. Given that EZH1 compensates the function of EZH2, inhibitors that target both EZH2 and EZH1 such as In line with therapeutic advances,combination therapy shall be explored becauseEZH2 inhibitors can be used together with inhibitors against other oncogenic pathways that act in parallel in cancer. Indeed, our recent studies demonstrated synergy of EZH2 and HDAC inhibitors to inhibit lymphoma clonogenic cell growth, induce apoptosis, and suppress growth of MCLsor aggressive c-MYC-associated lymphomas 75, 77 . The effects are at least partially due to disruption of c-MYC/EZH2-mediated miRNA silencing and vicious amplification loops ( Figure 3B ). In addition, combinationtreatment with EZH2 and BCL2 inhibitors outperformed the single-drug therapies in lymphoma models 56 . Lastly, given cooperationbetween DNA methylation and histone modification in transcriptional regulation, it would be of great interest to test if lymphoma cases with a higher degree of epigenetic silencing and hence reduced reversibility are less sensitive to PRC2 inhibitor single treatment but more responsive to a combined treatment with DNA demethylating agents.
Conclusion
Gene regulation by PcG complexes is critical for regulation of various biological programs related to normal development and oncogenesis. PcGaberration, caused by its deregulated expression, somatic mutation and chromosomal translocation, is common in various B-cell malignancies, PRC2 catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3) (panelA), which is recognized and bound by CBX proteins such as CBX7, a PRC1 subunit, to subsequently recruit PRC1 for induction of mono-ubiquitination of histone H2A at lysine 119 (H2AK119ub1) 7, 8 (panelB).Conversely, recent studies show that a variant form of PRC1 can act upstream of PRC2 to initiate formation of the polycomb domain; in this case, H2AK119ub1 serves as a PRC2 recruitment mechanism (panel C) [12] [13] [14] . In addition, EED is also shown to interact to PRC1 physically 15 . Me, trimethylation; Ub, ubiquitination. During B-cell differentiation, naïve B-cells enter the GC and EZH2 istranscriptionally up-regulated during GC B-cell maturation 26, 47 . Via induction of H3K27me3, EZH2then transcriptionally represses a myriad of downstream effector genes, which at least include the negative cell cycle regulators (CDKN2A and CDKN1A),B-cell differentiation-promoting transcription factors (IRF4 andBLIMP1/PRDM1), hence allowing for rapid expansion of immature B-cells 47, 56, 57 ; in addition,EZH2 protects GC B-cells from the genotoxic damages induced by activation-induced cytidinedeaminase (AID) 47 , an enzyme critical for immunoglobulin (Ig) affinity maturation via a mechanism of somatic hyper-mutation that modifies the Ig variable region (IgV) of the rearranged antibody genes in GC B-cells 21 . EZH2 levels decrease as B cells exit the GC, enabling derepression of EZH2-targeted genes and hence terminal differentiation 47, 56, 57 . However, EZH2 hyperactivity (either somatic mutation or overexpression) disrupts such fine equilibrium,enhances H3K27me3, and results in exaggerated silencing of EZH2 targeted genes, which then block GC For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From
